Osteosarcoma in dogs: treatment, prognosis and clinical trials

Currently enrolling

What is being offered: Distinct from UF's RNA-nanoparticle/anti-PD-1 radiation protocol: this vaccine is given at six visits about three weeks apart alongside six chemotherapy visits scheduled two weeks before each vaccine visit. Boosters may be offered every six months if appropriate. Eligibility evaluation does not guarantee enrollment; the referring veterinarian must complete UF's Oncology Referral Form.

Who may qualify: Confirmed cancer diagnosis required; Appendicular location; Planned amputation and chemo

Costs / coverage: ⚪ Owner-paid. Owners pay for the eligibility evaluation, amputation, chemotherapy, six study vaccine doses, additional diagnostics and subsequent visits. No financial incentive is offered. The study covers only treatment of a vaccine injection-site reaction, up to $100; no other costs are covered.

Contact: UF Oncology Staff — (352) 392-2235 to schedule an evaluation; Study Interest Form and required referring-veterinarian Oncology Referral Form on the official protocol page; VM-ClinicalStudies@ufl.edu for restricted-medication details

Official study / enrollment information →

Currently enrolling

What is being offered: RNA-nanoparticle vaccine made from UF-collected tumor cells plus anti-PD-1, both administered by approximately 30-minute IV infusion; hospital monitoring for 6–24 hours after each vaccine administration. Core biopsy is performed during radiation-planning CT before radiation. Distinct from UF's owner-paid post-amputation vaccine-plus-chemotherapy protocol. Referring veterinarian must complete UF's Oncology Referral Form.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Planned radiation; Pretreatment biopsy; Appendicular location

Costs / coverage: 🟡 Partially funded. Owners pay standard diagnosis and treatment, including initial evaluation, diagnostics, imaging, bloodwork, and radiation planning/treatment. The study covers RNA-vaccine production, vaccine-associated exams, immune-marker and safety laboratory testing at vaccine visits, indicated urinalysis, and adverse events on vaccine-administration days. Selected cases may receive imaging and/or radiation coverage. For immediate anaphylaxis within 12 hours of vaccination, up to an additional $1,000 of complication treatment may be covered.

Contact: UF Oncology Staff — (352) 392-2235; Study Interest Form / Oncology Referral Form on the official study page

Official study / enrollment information →

Active - Recruiting

What is being offered: Appendicular OSA primary removed; measurable metastasis limited to lungs; dog ≥20 kg. No chemotherapy in preceding 2–3 weeks; no current steroids or immune-modifying medication. Blood collection about two weeks before treatment, preparatory chemotherapy, CAR T-cell infusion and daily oral medications; visits days 1, 3, 7, 14, 28, 60.

Who may qualify: Confirmed cancer diagnosis required; Metastatic; Active tumor required; Primary removed; Measurable lung metastases; Min weight kg: 20; Appendicular location; Prior surgery; Planned chemo

May not qualify if: Metastases outside lungs; Concurrent immunomodulatory drugs; Corticosteroids; Current steroids; Immunosuppressive

Costs / coverage: 🟡 Partially funded. Owners pay initial cancer diagnostics and examination fees at every study visit. Study treatment, CAR T-cell manufacture/infusion, study diagnostics and bloodwork are covered; screening assistance is available, with up to $2,000 for study-related side effects.

Contact: CSU Flint Animal Cancer Center Clinical Trials — (970) 297-4001; online clinical-trial consult form

Official study / enrollment information →

Recruiting — listed on the current UW Veterinary Care oncology studies page

What is being offered: One randomized FLASH or conventional-dose-rate radiation treatment, weekly follow-ups, and amputation at approximately one month under the current study consent

Who may qualify: Active tumor required; Appendicular location; Planned amputation; Planned radiation

Costs / coverage: Study covers radiation therapy and amputation scheduled one month after study start. Medications prescribed for study-related side effects are not covered. Confirm screening and other owner-paid costs with the study team.

Contact: Dr. Tricia Hu — tghu@wisc.edu; Dr. Nathaniel Van Asselt — nvanasselt@wisc.edu; UW Oncology Service — 608-890-0422

Official study / enrollment information →

Now enrolling patients

What is being offered: Appendicular OSA; age >=1 year, >=44 lb, otherwise in good general health; cytologic/histologic confirmation. Current Ethos owner page lists 9 enrolling hospitals. An older AVMA registry listing contains additional historical sites; those are not promoted without current site-level confirmation.

Who may qualify: Confirmed cancer diagnosis required; Min weight lb: 44; Active tumor required; Appendicular location; Min age years: 1; Planned amputation

Costs / coverage: 🟡 Partially funded. All study-related visits are covered, including up to $4,000 toward amputation.

Contact: Contact participating Ethos hospital through official study page.

Official study / enrollment information →

Current enrolling clinical trial — July 2026 list

What is being offered: Appendicular OSA treated with stereotactic body radiation; patient-specific biomechanical modeling identifies dogs who may benefit from intramedullary stabilization.

Who may qualify: No metastasis; Active tumor required; Appendicular location; Planned radiation; Planned chemo

Costs / coverage: 🟡 Partially funded. Study covers pre-operative limb CT and gait assessment, implant placement/anesthesia, implant, fluoroscopy, histopathology, specified limb radiographs and gait follow-up. A $1,000 direct payment is provided after study completion. SBRT and carboplatin chemotherapy are not covered.

Contact: Ohio State Blue Buffalo Veterinary Clinical Trials Office — CVM-ClinicalTrials@osu.edu

Official study / enrollment information →

Current funded oncology clinical trial

What is being offered: Radiation to the affected limb followed by intratumoral JEN-101 at day 2 and week 2, then amputation at week 4

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Appendicular location; No metastasis; Planned radiation; Planned amputation

May not qualify if: Prior chemo; Prior local radiation; Prior immunotherapy; Prior steroids; Immunosuppressive

Costs / coverage: Partially funded after eligibility: radiation, JEN-101 and associated treatment-visit charges; follow-up abdominal ultrasound and chest radiographs; and up to $2,500 toward amputation at Illinois are covered. Owner pays screening, recheck exams/bloodwork and remaining amputation cost.

Contact: Rebecca Kamerer, Clinical Trials Coordinator — rmoss81@illinois.edu · 217-300-6453; appointments 217-333-5300

Official study / enrollment information →

Current funded oncology clinical trial

What is being offered: Up to eight once-weekly intravenous doses of Z-007 with baseline and week-9 CT; compassionate continuation may be offered for objective response

Who may qualify: Confirmed cancer diagnosis required; Metastatic; Measurable lung metastases; chemotherapy washout: 21 days; radiation washout: 7 days

May not qualify if: Immunosuppressive

Costs / coverage: Fully funded after eligibility: trial exams, bloodwork, Z-007 administration and CT scans are covered. Owner pays the initial exam and eligibility diagnostics.

Contact: Rebecca Kamerer, Clinical Trials Coordinator — rmoss81@illinois.edu · 217-300-6453; appointments 217-333-5300

Official study / enrollment information →

Currently enrolling

What is being offered: Current live Missouri oncology roster explicitly lists 'Evaluation of Timing of Carboplatin Chemotherapy post Amputation for Osteosarcoma.' Eligible dogs have an untreated bone tumor with cytologic sarcoma and positive ALP staining, no lung metastasis and no prior treatment; they must undergo complete amputation followed by six carboplatin doses. Carboplatin starts the day after surgery or immediately before discharge, with follow-up until metastasis. This is an interventional timing study, not merely observational.

Who may qualify: Confirmed cancer diagnosis required; No metastasis; Planned amputation and chemo

May not qualify if: Prior local radiation; Prior immunotherapy

Costs / coverage: The study covers chest radiographs and CBC/chemistry at the first chemotherapy visit. Owners are responsible for screening diagnostics, amputation and all six carboplatin treatments.

Contact: Oncology Clinical Trials Service 573-882-7821; muoncology@missouri.edu

Official study / enrollment information →

Open / currently enrolling

What is being offered: Thoracoscopic minimally invasive surgical removal of pulmonary metastatic nodules

Who may qualify: Confirmed cancer diagnosis required; Metastatic; Min weight lb: 11

Costs / coverage: 🟡 Partially funded. Study procedures are subsidized and provided at reduced cost; confirm the current owner contribution with the enrolling hospital.

Contact: Ethos Discovery enrollment request through official MIMIC study page

Official study / enrollment information →

Recruiting

What is being offered: Carboplatin combined with Laverdia-CA1 (verdinexor), a selective inhibitor of nuclear export (SINE)

Who may qualify: Confirmed cancer diagnosis required; Prior surgery; Post amputation; Planned chemo

Costs / coverage: 🟡 Partially funded. Laverdia-CA1 is provided free; sponsor contributes $150 per carboplatin visit (up to $600) and $25 per bloodwork visit (up to $100), with a 10% bill discount. Owners pay all additional costs and unrelated tests/procedures.

Contact: Carol Frederick, Clinical Trials Coordinator; Cornell University Hospital for Animals, (607) 253-3060. Apply through the official study page.

Official study / enrollment information →

Recruiting

What is being offered: Dog study of IV or intratumoral Z-007 for solid tumors including carcinomas, sarcomas and melanoma. Public criteria include a generally 2–7 cm repeat-biopsy-accessible tumor plus medical/laboratory requirements; no prior immunotherapy or autoimmune disease. Investigator prescreening required.

Who may qualify: Confirmed cancer diagnosis required; Min weight kg: 7; Measurable

May not qualify if: Prior immunotherapy

Costs / coverage: 🟡 Partially funded. Z-007 treatment through Day 63 and treatment of Z-007/biopsy-related side effects are covered; other owner costs should be confirmed with Tufts.

Contact: clinicaltrials@tufts.edu

Official study / enrollment information →

Currently enrolling at nine confirmed sites; Chicago, Richmond and Missouri are not enrolling

What is being offered: USDA-regulated EGFR/HER2 peptide-vaccine study led by Therajan. The current Canine Cancer Alliance status page identifies nine locations without a non-enrolling warning: Ventura, Edmonds, Pullman, Salt Lake City, Cleveland, Pittsburgh, Cincinnati, Phoenix and Stamford. Its same roster marks Chicago, Richmond and Columbia, Missouri as currently not enrolling. Stamford was separately confirmed on Veterinary Cancer Concierge Services' current trial page, which provides its intake pathway, eligibility materials and appointment location. Site-specific eligibility, scheduling and costs vary; MedVet restrictions apply only to its hospitals. Bridge also considers pulmonary carcinoma and high-grade mast cell tumor after records review, but those site-only indications are not mapped to the shared protocol record.

Who may qualify: Anticipated survival over 3 months; Standard of care therapy; Histology or long bone osa exception

May not qualify if: Other immunotherapy; Alternative therapy; Other clinical study

Costs / coverage: The investigational vaccine is provided at no charge; site visits, conventional treatment, administration and monitoring may be owner-paid. VCCS publishes a $695 charge for each vaccine appointment plus required testing. Confirm exact site-specific costs before enrollment.

Contact: Hope Veterinary Oncology — 805-626-6551; Bridge Animal Referral Center — 425-697-2272; Washington State University — 509-335-0711; MedVet Clinical Studies — clinicalstudies@medvet.com; MedVet Pittsburgh — oncology.pittsburgh@medvet.com; IVO — 602-841-0626; Veterinary Cancer Concierge Services — info@vetcancerconcierge.com.

Official study / enrollment information →

Actively recruiting — listed on current OVC canine oncology trials page

What is being offered: Pilot treatment study for confirmed osteosarcoma of the distal radius with no evidence of metastasis. No previous surgery or radiation for the osteosarcoma. Prior chemotherapy and/or bisphosphonate treatment is evaluated case-by-case. Requires visits to SickKids in Toronto and OVC in Guelph.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; No metastasis; Appendicular location; Distal radius osa

May not qualify if: Prior local radiation; Prior target tumor surgery

Costs / coverage: 🟡 Partially funded. The study covers MRI(s), HIFU treatment, associated anesthesia, study biopsies and analyses.

Contact: OVC Clinical Trials — ovc.clinicaltrials@uoguelph.ca; official study contact form

Official study / enrollment information →

Actively recruiting — listed on CSU current clinical trials page

What is being offered: Custom 3D-printed implant replaces affected distal-radius bone, followed by six chemotherapy treatments every three weeks and follow-up every two months up to 20 months. Frequent postoperative bandage changes are required; owner must agree to donate the limb after death.

Who may qualify: Active tumor required; Primary bone tumor; No metastasis; Appendicular location; Distal radius osteosarcoma; Giant breed or weight at least 40kg; Planned surgery; Planned chemo

May not qualify if: Immunosuppressive

Costs / coverage: 🟡 Partially funded. PET-CT/anesthesia, custom 3D-printed implant, surgery/hospitalization, six chemotherapy treatments and study follow-up imaging up to 20 months are covered, with up to $5,825 for surgical complications. Owners pay initial diagnosis/additional recommended tests, care outside CSU and complications beyond coverage.

Contact: CSU Flint Animal Cancer Center Clinical Trials — (970) 297-4001; online clinical-trial consult form

Official study / enrollment information →

Actively recruiting — listed on CSU current clinical trials page

What is being offered: Primary CSU current-trials page and study page list this study as enrolling as of 2026-09-09. A Veterinary Clinical Trials Registry profile says the study is on hold due to carboplatin shortage; per catalog policy, current institution study page is primary for enrollment status. Registry discrepancy retained for future recheck.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Appendicular location; Weight bearing; Planned chemo; Stable pain medication 7d; Bone medication washout 30d

May not qualify if: Prior chemo; Prior radiation; Bone metastasis

Costs / coverage: Study covers pre-enrollment CBC, chemistry, urinalysis, chest and limb radiographs and tumor aspirate/biopsy; after enrollment it covers one carboplatin treatment, study rechecks, repeat bloodwork and limb radiographs, plus initial anti-nausea/anti-diarrheal medications. Owners pay standard pain medication for the seven days before enrollment and additional chemotherapy side-effect care beyond the initial study-provided medication.

Contact: CSU Flint Animal Cancer Center Clinical Trials — (970) 297-4001; online clinical-trial consult form

Official study / enrollment information →

Actively recruiting — confirmed on the institution’s current clinical-trials page

What is being offered: For dogs with pulmonary metastatic osteosarcoma after amputation and chemotherapy; combines toceranib, losartan and ladarixin with a tumor vaccine.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Primary removed; Measurable lung metastases; Post amputation; Prior chemo; Metastatic

Costs / coverage: 🟡 Partially funded. Study provides the oral drugs and tumor vaccines and covers nearly all study costs; limited specified bloodwork/supportive medications remain owner-paid.

Contact: clinicaltrials@tufts.edu

Official study / enrollment information →

Current

What is being offered: Investigational therapy, chemotherapy, immunotherapy and combination approaches under a prospective compassionate-use protocol

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Min weight kg exclusive: 2.5; min expected survival weeks: 3 weeks; Adequate organ function

May not qualify if: Severe systemic disease

Costs / coverage: ⚪ Owner-paid. The protocol brochure states that owners fully pay for the study, although possible subsidies may be available.

Contact: Paige Neumann, Research Study Coordinator — 214-645-6221; VROC@UTSouthwestern.edu

Official study / enrollment information →

Open and recruiting — listed on the current Johns Hopkins CIGAT clinical-trials page

What is being offered: Treatment trial for histopathologically confirmed canine osteosarcoma. Eligible dogs receive PET-CT and either cryotherapy or two doses of tumor-injected immunotherapy before required amputation at about two weeks, followed by chemotherapy. Johns Hopkins lists no prior osteosarcoma treatment or chemotherapy for other cancers and requires the dog to be systemically healthy apart from osteosarcoma.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Planned amputation and chemo

May not qualify if: Prior chemo; Prior osteosarcoma treatment

Costs / coverage: 🟡 Partially funded. Study covers PET-CT/CT imaging, cryotherapy or intratumoral immunotherapy, study-related medications and follow-up imaging/blood tests; required amputation and chemotherapy are owner-paid.

Contact: Johns Hopkins CIGAT — 410-502-7325; contact through the official clinical-trials page

Official study / enrollment information →

Actively recruiting — listed on Penn Vet's current Comparative Immunotherapy clinical-trials page

What is being offered: Investigational B7H3-targeted CAR-iNKT cell therapy for dogs with newly diagnosed osteosarcoma. This is a distinct protocol from Penn's CAR-iNKT study for dogs with metastatic osteosarcoma. Treatment is followed by amputation and standard-of-care chemotherapy; full eligibility requires Penn Vet prescreening.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Newly diagnosed; No metastasis; Min weight kg: 23; Appendicular location; Planned amputation and chemo

Costs / coverage: 🟢 Fully funded — Including initial screening; no cost to owners. Screening, confirmatory biopsy/B7H3 testing, CAR-iNKT therapy, amputation/post-op care, standard chemotherapy and study monitoring are covered.

Contact: Mary Beth Boland, CVT — mboland@vet.upenn.edu — (215) 898-5098

Official study / enrollment information →

Active - Recruiting

What is being offered: Phase I B7-H3-targeted CAR-iNKT cell-therapy study for dogs with metastatic osteosarcoma. Penn Vet's official current clinical-trial page is the primary status source; full protocol eligibility requires Penn prescreening.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Metastatic; Post amputation; Prior chemo; Appendicular location; Min weight kg: 18; chemotherapy washout: 56 days; Measurable lung metastases; B7h3 expression and prior carboplatin

Costs / coverage: Penn Vet states costs associated with the study treatment are covered; confirm current screening and non-study costs during prescreening.

Contact: Nicola Mason, BVetMed, PhD, DACVIM, FRCVS — nmason@vet.upenn.edu — (215) 898-3996

Official study / enrollment information →

Currently enrolling

What is being offered: Partial HIFU ablation followed by limb amputation and adjuvant carboplatin chemotherapy

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Min age years: 1; Appendicular osteosarcoma; No metastasis; Suitable hifu acoustic window; Planned amputation; Planned carboplatin; Min weight kg exclusive: 8

May not qualify if: Metastatic; Recent chemotherapy 3w; Recent steroids 2w; Poor performance status

Costs / coverage: 🟡 Partially funded — HIFU and functional imaging are covered, up to $2,600 is provided toward amputation, and chemotherapy recheck visits are covered. Owners pay initial staging, remaining surgery costs, carboplatin administration and surgery-related complications.

Contact: Purdue Tumor Ablation Lab — TumorAblation@purdue.edu; Purdue Veterinary Hospital Referrals — 765-494-1107

Official study / enrollment information →

Recruiting

What is being offered: Tufts tests olaparib, temozolomide or VLS-1488 instead of standard carboplatin. Group A enrolls dogs with newly diagnosed appendicular osteosarcoma, no obvious metastasis and planned amputation; dogs receive six days of study drug before amputation and restart it after surgery. Group B enrolls previously treated dogs with measurable metastasis to lung, skin/subcutis or abdomen but no bone metastasis and treats until progression. Both groups require at least 15 kg body weight, acceptable organ function and study-team prescreening.

Who may qualify: Active tumor required; Min weight kg: 15; Eligible cohorts: Osa location: Appendicular — limb bone; Metastasis: No known metastases; Prior procedure: Other; Required preferences: Surgery; Surgery: Yes; Prior procedure: Amputation; Metastasis: Confirmed metastases

May not qualify if: Concurrent small molecule therapy

Costs / coverage: 🟡 Partially funded. Screening is covered, Group A receives a $1,500 amputation credit, and all post-amputation study drugs and treatment of study-related side effects are covered.

Contact: Tufts Clinical Trials Office — clinicaltrials@tufts.edu; owner eligibility questionnaire on the official page

Official study / enrollment information →

Recruiting

What is being offered: Single highly focused radiation dose for dogs with 2–10 progressive pulmonary metastatic nodules. The primary tumor, regional nodes and any non-pulmonary metastases must already be controlled; progression must be documented over 6–8 weeks, and all progressive lung lesions at least 5 mm must be safely treatable. Prior systemic therapy is allowed; cytotoxic chemotherapy pauses around SABR, while tolerated targeted therapy or immunotherapy may continue with radiation-oncologist approval. Tufts prescreening is required.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Metastatic; Measurable lung metastases; Planned radiation

Costs / coverage: 🟡 Partially funded. The study covers SABR, the one-month follow-up, adverse-event rechecks related to lung toxicity, and up to $860 toward the 2–3-month CT visit. Owners pay pre-enrollment bloodwork, chest imaging, treatment-planning CT, and diagnostic confirmation.

Contact: Tufts Clinical Trials Office — clinicaltrials@tufts.edu; owner and referring-veterinarian prescreening questionnaires on the official page

Official study / enrollment information →

Currently listed as a funded clinical trial on the Illinois master roster

What is being offered: Three consecutive days of SBRT followed by local dendritic-cell homing hydrogel; weekly follow-up for five weeks

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Appendicular location; No metastasis; Min age years exclusive: 1; Min weight kg: 5; Planned radiation; Anesthesia candidate; steroid washout days: 14 days

May not qualify if: Prior chemo; Prior local radiation; Prior immunotherapy; Current steroids; Immunosuppressive

Costs / coverage: Fully funded after eligibility: CT, biopsy, three-day SBRT, hydrogel injection, study recheck exams and bloodwork. Owners pay the initial consultation (approximately $250), eligibility diagnostics, pain medication and unrelated care.

Contact: Rebecca Kamerer, Clinical Trials Coordinator — rmoss81@illinois.edu; 217-300-6453. Appointments: 217-333-5300.

Official study / enrollment information →